Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Butylated Hydroxytoluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.36 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylated Hydroxytoluene SCHEMBL7738522 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6908300 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL17835978 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6901302 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL20455508 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL23090058 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL4826096 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL4820691 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL17836004 | 0.92 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1TYRCA2POLB | |
| Butylated Hydroxytoluene SCHEMBL6039994 | 0.92 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1TYRCA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104628808-B | The synthetic method of a kind of pregnant steroid-1,4,9 (11), 16 (17)-tetraene-3,20-diketone and intermediate thereof | 苏州汉酶生物技术有限公司 | 2017-01-04 | — | — | CN | claimed |
| CN-103087139-B | A kind of canrenone derivatives class steroidal compounds, its preparation method and the purposes in preparing eplerenone thereof | 中国科学院上海药物研究所 | 2016-08-03 | — | — | CN | claimed |
| US-8552182-B2 | Method for producing a 3-(substituted-oxy)-4-pyridazinol derivative | MITSUI CHEMICALS AGRO, INC. (JP) | 2013-10-08 | — | — | US | claimed |
| US-20120184736-A1 | METHOD FOR PRODUCING A 3-(SUBSTITUTED-OXY)-4-PYRIDAZINOL DERIVATIVE | MITSUI CHEMICALS AGRO, INC (JP) | 2012-07-19 | — | — | US | claimed |
| EP-0434469-B1 | Hydrogenation catalyst composition and process for hydrogenating olefinically unsaturated polymer using the same | JAPAN SYNTHETIC RUBBER CO LTD (JP) | 1995-02-22 | — | — | EP | claimed |
| EP-0339986-B1 | NOVEL CATALYST FOR HYDROGENATION OF POLYMER AND PROCESS FOR HYDROGENATING POLYMER WITH THE CATALYST | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1992-12-02 | — | — | EP | claimed |
| EP-0434469-A2 | Hydrogenation catalyst composition and process for hydrogenating olefinically unsaturated polymer using the same | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1991-06-26 | — | — | EP | claimed |
| EP-0339986-A1 | Novel catalyst for hydrogenation of polymer and process for hydrogenating polymer with the catalyst | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1989-11-02 | — | — | EP | claimed |
| JP-1275605-A | — | — | None | — | — | JP | disclosed |
| WO-2026107171-A1 | PRODUCTION OF EPSILON-CAPROLACTAM FROM NYLON-6 VIA DEPOLYMERIZATION CATALYSTS | NORTHWESTERN UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3892652-B1 | POLYBUTADIENE, POLYBUTADIENE PRODUCTION METHOD, POLYBUTADIENE COMPOSITION, TIRE, AND RESIN MEMBER | BRIDGESTONE CORP (JP) | 2025-04-30 | — | — | EP | disclosed |
| US-12084536-B2 | Polybutadiene, method of producing polybutadiene, polybutadiene composition, tire, and resin member | BRIDGESTONE CORPORATION (JP) | 2024-09-10 | — | — | US | disclosed |
| EP-0099329-B1 | DITHIO COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE | Zyma SA (CH) | 1990-10-31 | — | — | EP | disclosed |
| US-4946861-A | TREATMENT OF LIVER DISORDERS | ZYMA SA (CH) | 1990-08-07 | — | — | US | disclosed |
| JP-H01275605-A | METHOD OF HYDROGENATION OF POLYMER AND CATALYST | JAPAN SYNTHETIC RUBBER CO LTD | 1989-11-06 | — | — | JP | disclosed |
| EP-0339986-A1 | Novel catalyst for hydrogenation of polymer and process for hydrogenating polymer with the catalyst | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4818765-A | TREATING LIVER, RESPIRATORY TRACT, VASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0099329-A1 | Dithio compounds, pharmaceutical preparations containing them and their use | Zyma SA (CH) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184736-A1 | METHOD FOR PRODUCING A 3-(SUBSTITUTED-OXY)-4-PYRIDAZINOL DERIVATIVE | CYP4F3, CYP4F2, PNPO | SMN1; SMN2 4104/4885ALDH1A1 603/4885TYR 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.